Trade

with

Data not available

Open

-

Previous Close

-

Volume (Avg)

-

Day's Range

-

52Wk Range

-

Market Cap.

-

P/E Ratio (EPS

-

Dividend Rate ( Yield )

-

Beta

1.22

Shares Outstanding

76.01M

P/E Ratio (EPS)

-

AdChoices
Company Profile

Sector

Healthcare

Industry

Biotechnology

Type

Distressed

Style

Small Core

GTx, Inc. is a Delaware corporation incorporated on September 24, 1997. It operates as a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules that selectively target hormone pathw...moreays to treat cancer, osteoporosis and bone loss, muscle loss and other serious medical conditions. The Company develops selective androgen receptor modulators, or SARMs, to prevent and treat muscle wasting in patients with cancer and other musculoskeletal wasting or muscle loss conditions, including chronic sarcopenia (age related muscle loss). They are conducting the POWER 1 and POWER 2 (Prevention and treatment Of muscle Wasting in patients with cancER) pivotal Phase III clinical trials evaluating enobosarm for the prevention and treatment of muscle wasting in patients...more with advanced non-small cell lung cancer. The Company is developing GTx-758, an oral luteinizing hormone, or LH, inhibitor for the treatment of advanced prostate cancer. In preclinical in vitro and in vivo models, GTx-758 has demonstrated the potential to reduce testosterone to castrate levels without causing certain estrogen deficiency side effects such as bone loss and hot flashes. The Company’s most advanced product candidate, toremifene, is being developed for the prevention of bone fractures and treatment of other estrogen deficiency side effects of ADT in men with prostate cancer and for the prevention of prostate cancer in high risk men with high grade PIN. Additionally the company is developing Capesaris (GTx-758), an oral nonsteroidal selective estrogen receptor (ER) alpha agonist, for secondary hormonal therapy in men with metastatic castration resistant prostate cancer, or CRPC, and, potentially, as a primary treatment for advanced prostate cancer used in combination with androgen deprivation therapy, or ADT. It faces competition from many different sources, including commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies and private and public research institutions.lessless

Key People

Mr. Marc S. Hanover

COO/Founder/President/CEO

Mr. J.R. Hyde, III

Chairman of the Board/Director

Mr. Jason T. Shackelford

CFO/Controller/Other Corporate Officer/Chief Accounting Officer

Jeffrey G. Hesselberg

Vice President, Divisional

Henry P. Doggrell

General Counsel/Other Executive Officer/Secretary/Vice President

Incorporated

1997

Employees

-